natgillin/translations-raw huggingface dataset:
In patients with significant renal impairment the activity of radioiodine should be carefully selected by the nuclear medicine physician. 
U bolesnika sa značajnim oštećenjem bubrežne funkcije dozu radioaktivnog joda treba pažljivo odrediti liječnik specijalist nuklearne medicine.
In one of the studies, two dose regimens were examined: 0.9 mg intramuscular every 24 hours for two doses (0.9 mg x 2) and 0.9 mg intramuscular every 72 hours for three doses (0.9 mg x 3). 
U jednom od njih ispitivana su dva protokola doziranja: dvije doze od 0,9 mg intramuskularno u razmaku od 24 sata (0,9 mg x 2) i tri doze od 0,9 mg intramuskularno u razmaku od 72 sata (0,9 mg x 3).
Cardiac disorders palpitations 
Srčani poremećaji palpitacije
Due to a lack of data on the use of Thyrogen in children, Thyrogen should be given to children only in exceptional circumstances. 
Zbog nedostatka podataka o primjeni lijeka Thyrogen u djece, lijek Thyrogen treba dati djeci samo u iznimnim okolnostima.
Dispose of any unused solution immediately. 
Odmah zbrinuti svu neiskorištenu otopinu.
The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP. 
Nositelj odobrenja obavljat će zadane farmakovigilancijske aktivnosti i intervencije, detaljno objašnjene u dogovorenom Planu upravljanja rizikom (RMP), a koji se nalazi u Modulu 1.8.2
Thyrogen does not contain preservatives. 
Thyrogen ne sadrži konzervanse.
The Thyrogen solution should be injected within three hours, however the Thyrogen solution will stay chemically stable for up to 24 hours, if kept in a refrigerator (between 2°C and 8°C). 
Otopina lijeka Thyrogen mora se injicirati u roku od tri sata; međutim, otopina lijeka Thyrogen će ostati kemijski stabilna do najduže 24 sata ako se čuva u hladnjaku (između 2°C i 8°C).
Effect on tumour growth and/or size 
Učinak na rast i/ili veličinu tumora:
The use of Thyrogen in patients with reduced liver function does not warrant special considerations. 
Primjena lijeka Thyrogen u bolesnika s oslabljenom funkcijom jetre ne zahtijeva posebno razmatranje.
• if you have kidney disease that requires dialysis and he will decide how much Thyrogen to give to you as you may have more chance of experiencing headache and nausea. 
• ako imate bolest bubrega koja zahtijeva dijalizu, a liječnik će odlučiti koliko lijeka Thyrogen trebate primiti s obzirom da postoji veća vjerojatnost da dobijete glavobolju i mučninu.
There are no known drug interactions with Thyrogen and the thyroid hormones you may be taking. 
Nema poznatih interakcija s lijekom Thyrogen i hormonima štitnjače koje možda uzimate.
After injection, the mean peak (Cmax) level obtained was 116 ± 38 mU/l and occurred approximately 13 ± 8 hours after administration. 
Srednja vrijednost vršne koncentracije (Cmax) postignuta nakon injekcije iznosila je 116 ± 38 mU/l i nastupila je približno 13 ± 8 sati nakon primjene.
Each vial of Thyrogen is for single use only. 
Svaka bočica lijeka Thyrogen namijenjena je samo za jednokratnu uporabu.
The powder for solution for injection has to be reconstituted with water for injection. 
Prašak za otopinu za injekciju mora se rekonstituirati s vodom za injekcije.
Total number of patients with recurrence (5.4 years) Low activity RAI (1.1 GBq) High activity RAI (3.7 GBq) 
Ukupan broj bolesnika s povratom bolesti (5,4 godine) Radioaktivni jod niske aktivnosti (1,1 GBq) Radioaktivni jod visoke aktivnosti(3,7 GBq)
It is unknown whether thyrotropin alfa /metabolites are excreted in human milk. 
Nije poznato izlučuju li se tireotropin alfa/metaboliti u majčino mlijeko.
If the metastases are present in narrow spaces e.g. intracerebral (in the brain) or in the spinal cord, patients could experience symptoms which can occur quickly such as partial paralysis affecting one side of the body (hemiparesis), breathing problems or loss of vision. 
Ako su se metastaze razvile u uskim prostorima, primjerice u intracerebralnom prostoru (u mozgu) ili u kralježničnoj moždini, bolesnici mogu brzo razviti simptome poput djelomične paralize jedne strane tijela (hemipareza), problema s disanjem ili gubitka vida.
• hypersensitivity (allergic reactions), these reactions include hives (urticaria), itching, flushing, difficulty in breathing and rash. 
• preosjetljivost (alergijske reakcije); ove reakcije uključuju koprivnjaču (urtikariju), svrbež, navale crvenila, otežano disanje i osip.
Do not use this medicine if you notice foreign particles, cloudiness or discoloration. 
Ne primjenjujte lijek ako primijetite strane čestice, zamućenje ili promjenu boje.
In clinical trials with thyrotropin alfa, which produces a short-term increase in serum TSH levels, no case of tumour growth has been reported. 
U kliničkim ispitivanjima tireotropina alfa, koji izaziva kratkoročno povišenje razina TSH-a u serumu, nije prijavljen niti jedan slučaj rasta tumora.
Based on 684 evaluable patients, the overall ablation success rate assessed by neck ultrasounds and stimulated Tg levels was 92%, without any statistically significant difference among the four groups. 
Na temelju 684 bolesnika dostupna za procjenu, ukupna stopa uspješnosti ablacije ocijenjena ultrazvučnim pregledima vrata i razinama Tg nakon stimulacije iznosila je 92%, a između te četiri skupine nije bilo statistički značajne razlike.
When the powder is dissolved the total volume in the vial is 1.2 ml. 
Kad se prašak otopi, ukupan volumen u bočici iznosi 1,2 ml.
The HiLo study randomised 438 patients (tumour stages T1-T3, Nx, N0 and N1, M0) at 29 centres. 
U ispitivanju HiLo randomizirano je 438 bolesnika (stadiji tumora T1-T3, Nx, N0 i N1, M0) u 29 centara.
A suggested treatment in case of overdose would be the reestablishment of fluid balance and administration of an antiemetic may also be considered. 
Predloženo liječenje u slučaju predoziranja sastoji se u ponovnom uspostavljanju ravnoteže tekućine, a može se razmotriti i primjena antiemetika.
Diagnostic scintigraphy should be performed 48 to 72 hours following radioiodine administration, whereas post-ablation scintigraphy may be delayed additional days to allow background activity to decline. 
Dijagnostičku scintigrafiju treba provesti 48 do 72 sata nakon primjene radioaktivnog joda, dok se scintigrafija nakon ablacije može odgoditi za nekoliko dana dok se ne smanji pozadinska aktivnost.
The tables below provide long term follow up information for the ESTIMABL1 and HiLo studies 
Niže navedene tablice sadrže podatke dugoročnog praćenja iz ESTIMABL1 i HiLo ispitivanja.
Thyrotropin alfa (recombinant human thyroid stimulating hormone) is a heterodimeric glycoprotein produced by recombinant DNA technology. 
Tireotropin alfa (rekombinantni humani hormon koji stimulira štitnjaču) je heterodimerni glikoprotein proizveden tehnologijom rekombinantne DNK.
The reconstituted solution can be stored for up to 24 hours in a refrigerator (2°C - 8°C) under protection from light, while avoiding microbial contamination. 
Rekonstituirana se otopina može čuvati do 24 sata u hladnjaku (2°C - 8°C), zaštićena od svjetlosti i pritom izbjegavajući mikrobiološku kontaminaciju.
Careful evaluation of benefit-risk relationships should be assessed for Thyrogen administration in high risk elderly patients who have heart disease (e.g. valvular heart disease, cardiomyopathy, coronary artery disease, and prior or current tachyarrhythmia including atrial fibrillation) and have not undergone thyroidectomy. 
Treba pažljivo procijeniti odnos rizika i koristi primjene lijeka Thyrogen u visokorizičnih starijih bolesnika koji boluju od srčane bolesti (npr. bolesti srčanih zalistaka, kardiomiopatije, bolesti koronarnih arterija te ranije ili trenutno postojeće tahiaritmije uključujući fibrilaciju atrija), a nisu bili podvrgnuti tireoidektomiji.
The cDNAs encode for an alpha subunit of 92 amino acid residues containing two N-linked glycosylation sites, and a beta subunit of 118 residues containing one N-linked glycosylation site. 
Komplementarne DNK (cDNA) kodiraju za alfa podjedinicu od 92 aminokiselinska ostatka s dva N-vezana glikozilacijska mjesta i beta podjedinicu od 118 aminokiselinskih ostataka s jednim N-vezanim glikozilacijskim mjestom.
Patients studied were adults (>18 years), with newly diagnosed differentiated papillary or follicular thyroid carcinoma, including papillary-follicular variant, characterised, principally (54 of 60), as T1-T2, N0-N1, M0 (TNM classification). 
U ispitivanju su sudjelovali odrasli bolesnici (> 18 godina) s novodijagnosticiranim diferenciranim papilarnim ili folikularnim karcinomom štitnjače, uključujući i papilarno-folikularni tip, koji su uglavnom (54 od 60) klasificirani kao T1-T2, N0-N1, M0 (TNM klasifikacija).
To provide sufficient volume to allow accurate dispensing, each vial of Thyrogen is formulated to contain an overfill of 0.2 ml. 
Kako bi se osigurao dovoljan volumen za precizno doziranje, svaka bočica lijeka Thyrogen sadrži suvišak od 0,2 ml.
High activity dose RAI (3.7 GBq) 
Doza radioaktivnog joda visoke aktivnosti (3,7 GBq)
One of the effects is that it stimulates any remaining thyroid tissue to take up iodine which is important for radioiodine imaging. 
Jedan od njegovih učinaka je stimulacija preostalog tkiva štitnjače da nakuplja jod koji je važan za pretragu radioaktivnim jodom.
Data on radioiodine kinetics indicate that the clearance of radioiodine is approximately 50% greater while euthyroid than during the hypothyroid state when renal function is decreased, thus resulting in less radioiodine retention in the body at the time of imaging. 
Podaci o kinetici radioaktivnog joda ukazuju na to da je njegov klirens približno 50% veći u eutireozi nego u stanju hipotireoze, u kojemu je funkcija bubrega smanjena, što dovodi do manje retencije radioaktivnog joda u tijelu u vrijeme scintigrafije.
Thyrogen should only be administered into the buttock muscle. 
Thyrogen se treba primijeniti samo u mišić stražnjice.
As assessed by radioiodine imaging and stimulated Tg levels (n = 421), ablation success rates were approximately 86% in all four treatment groups. 
Prema nalazima radiojodne scintigrafije i razinama Tg nakon stimulacije (n = 421), stopa uspješnosti ablacije iznosila je približno 86% u sve četiri terapijske skupine.
Quality of life was significantly reduced following thyroid hormone withdrawal, but maintained following either dosage regimen of Thyrogen in both indications. 
Kvaliteta života bolesnika značajno se smanjila nakon prekida terapije tireoidnim hormonom, dok je bila održana pri oba režima doziranja lijeka Thyrogen u obje indikacije.
Formal interaction studies between Thyrogen and other medicinal products have not been performed. 
Nisu provedena formalna ispitivanja interakcija lijeka Thyrogen s drugim lijekovima.
Clear Type I glass 5 ml vials. 
Prozirne staklene bočice (staklo tip I) od 5 ml.
The presence of Tg autoantibodies can be expected in 18-40% of patients with differentiated thyroid cancer and may cause false negative serum Tg measurements. 
Tg autoprotutijela može se očekivati u 18-40% bolesnika s diferenciranim karcinomom štitnjače i može biti razlogom lažno negativnog nalaza mjerenja tireoglobulina u serumu.
Recurrence rate (5 years) Recurrence rate (7 years) 
Stopa povrata bolesti (3 godine) Stopa povrata bolesti (5 godina) Stopa povrata bolesti (7 godina)
Thyrogen powder must be dissolved in water for injection. 
Thyrogen prašak mora se otopiti u vodi za injekcije.
Diagnostic scanning should be performed 48 to 72 hours after the radioiodine administration (72 to 96 hours after the final injection of Thyrogen). 
Dijagnostičko snimanje mora se obaviti 48 do 72 sata nakon davanja radioaktivnog joda (72 do 96 sati nakon zadnje injekcije lijeka Thyrogen).
There is a theoretical possibility that Thyrogen, like thyroid hormone withdrawal, may lead to stimulated tumour growth. 
Postoji teoretska mogućnost da Thyrogen, kao i prekid terapije tireoidnim hormonom, može dovesti do stimuliranja rasta tumora.
Therefore, careful evaluation of individual risk-benefit is necessary for patients with significant residual thyroid tissue. 
Stoga je potrebno pažljivo procijeniti odnos rizika i koristi u svakog pojedinog bolesnika sa značajnim ostatnim tkivom štitnjače.
It is not known whether Thyrogen can cause foetal harm when administered to a pregnant woman or whether Thyrogen can affect reproductive capacity. 
Nije poznato može li Thyrogen primijenjen u trudnica naštetiti plodu ili utjecati na reproduktivnu sposobnost.
Low activity dose RAI (1.1 GBq) 
Doza radioaktivnog joda niske aktivnosti (1,1 GBq)
It has comparable biochemical properties to natural human Thyroid Stimulating Hormone (TSH). 
Njegova su biokemijska svojstva usporediva sa svojstvima prirodnog humanog hormona koji stimulira štitnjaču (TSH).
What you need to know before you use Thyrogen 
Što morate znati prije nego počnete primjenjivati Thyrogen
This factor should be considered when selecting the activity of radioiodine for use in radioiodine imaging. 
Tu činjenicu treba uzeti u obzir kada se određuje aktivnost radioaktivnog joda potrebna za radiojodnu scintigrafiju.
Pack sizes: one or two vials of Thyrogen per carton. 
Veličine pakiranja: jedna ili dvije bočice lijeka Thyrogen u kutiji.
Two patients had nausea after 2.7 mg IM dose, and in one of these patients nausea was also accompanied by weakness, dizziness and headache. 
Dva su bolesnika imala mučninu nakon primjene i.m. doze od 2,7 mg, a u jednoga od njih uz mučninu su se javili i slabost, omaglica i glavobolja.
This patient received 0.3 mg of Thyrogen as a single intravenous (IV) bolus and, 15 minutes later experienced severe nausea, vomiting, diaphoresis, hypotension and tachycardia. 
Taj je bolesnik primio 0,3 mg lijeka Thyrogen u obliku jednokratnog intravenskog (i.v.) bolusa te je nakon 15 minuta imao jaku mučninu, povraćanje, znojenje, hipotenziju i tahikardiju.
Warnings and precautions Talk to your doctor or pharmacist before using Thyrogen 
Obratite se svom liječniku ili ljekarniku prije nego primijenite lijek Thyrogen:
Your treatment should be supervised by a doctor who has expertise in thyroid cancer. 
Liječenje mora nadgledati liječnik s iskustvom u liječenju karcinoma štitnjače.
In summary, these studies support the efficacy of low activity radioiodine plus thyrotropin alpha (with reduced radiation exposure). 
Sažeto, ova ispitivanja dokazuju djelotvornost radioaktivnog joda niske aktivnosti i tireotropina alfa (sa smanjenom izloženošću zračenju).
It is possible that Thyrogen may also cause tumour growth. 
Postoji mogućnost da i Thyrogen izaziva rast tumora.
Thyrogen should not be administered intravenously. 
Thyrogen se ne smije primijeniti intravenski.
Genzyme Europe B.V., Paasheuvelweg 25, 1105 BP Amsterdam, The Netherlands 
Paasheuvelweg 25, 1105 BP Amsterdam Nizozemska
This was thought to be related to the elevated thyroid stimulating hormone (TSH) levels over a longer period. 
Smatralo se da je to povezano s povećanim vrijednostima hormona koji stimulira štitnjaču (TSH) tijekom duljeg vremena.
Information from post marketing surveillance, as well as published information, suggests that elimination of Thyrogen is significantly slower in dialysis-dependent end stage renal disease (ESRD) patients, resulting in prolonged elevation of thyroid stimulating hormone (TSH) levels for several days after treatment. 
Podaci dobiveni praćenjem nakon stavljanja lijeka u promet kao i objavljeni podaci ukazuju da je eliminacija lijeka Thyrogen značajno sporija u bolesnika u terminalnoj fazi bubrežne bolesti ovisnih o dijalizi, što rezultira produljenim povišenjem vrijednosti hormona koji stimulira štitnjaču (TSH) tijekom nekoliko dana nakon liječenja.
In patients with well-differentiated thyroid cancer, a near total or total thyroidectomy is performed. 
Bolesnike s dobro diferenciranim karcinomom štitnjače podvrgava se gotovo potpunoj ili potpunoj tireoidektomiji.
Your doctor or nurse will inject 1.0 ml of the Thyrogen solution. 
Liječnik ili medicinska sestra će Vam ubrizgati 1,0 ml Thyrogen otopine.
Package size: one or two vials per carton. 
Veličina pakiranja: jedna ili dvije bočice u kutiji.
The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal. 
popis) predviđenom člankom 107.c stavkom 7. Direktive 2001/83/EZ i svim sljedećim ažuriranim verzijama objavljenima na europskom internetskom portalu za lijekove.
Do not shake the solution. 
Ne tresite otopinu.
It is not known whether Thyrogen can affect fertility in humans. 
Plodnost Nije poznato može li Thyrogen utjecati na plodnost u ljudi.
The adverse reactions mentioned in the table, combine adverse reactions in the six prospective clinical trials (N=481) and undesirable effects that have been reported to Genzyme after licensure of Thyrogen. 
Nuspojave navedene u tablici objedinjuju nuspojave iz šest prospektivnih kliničkih ispitivanja (N=481) i nuspojave prijavljene tvrtki Genzyme nakon davanja odobrenja za stavljanje u promet lijeka Thyrogen.
The pH of the Thyrogen solution is approximately 7.0. 
pH vrijednost Thyrogen otopine je približno 7,0.
Shelf-life after reconstitution 
Rok valjanosti nakon rekonstitucije
It also stimulates the production of thyroglobulin and thyroid hormones if there is any thyroid tissue left. 
Također stimulira stvaranje tireoglobulina i hormona štitnjače ako je preostao dio tkiva štitnjače.
The pharmacokinetics of Thyrogen were studied in patients with well-differentiated thyroid cancer following a single 0.9 mg intramuscular injection. 
Farmakokinetika lijeka Thyrogen ispitivana je u bolesnika s dobro diferenciranim karcinomom štitnjače nakon jedne intramuskularne injekcije u dozi od 0,9 mg.
Your medicine will be injected by a doctor or a nurse. 
Vaš liječnik ili medicinska sestra.
If you are given more Thyrogen than you should receive Patients who accidentally received too much Thyrogen have reported nausea, weakness, dizziness, headache, vomiting and hot flashes. 
Bolesnici koji su slučajno primili previše lijeka Thyrogen prijavili su mučninu, slabost, omaglicu, glavobolju, povraćanje i navale vrućine.
Skin and subcutaneous tissue disorders urticaria, rash pruritus, hyperhidrosis 
Poremećaji kože i potkožnog tkiva urtikarija, osip pruritus, hiperhidroza
• if you have reduced kidney function and he will decide how much radioiodine to give you. 
• ako imate oslabljenu funkciju bubrega, a liječnik će odlučiti koliko radioaktivnog joda trebate primiti.
In clinical trials, no interactions were observed between Thyrogen and the thyroid hormones triiodothyronine (T3) and thyroxine (T4) when administered concurrently. 
U kliničkim ispitivanjima nisu zamijećene interakcije prilikom istodobne primjene lijeka Thyrogen i hormona štitnjače trijodtironina (T3) i tiroksina (T4).
Musculoskeletal and connective tissue disorder neck pain, back pain arthralgia, myalgia 
Poremećaji mišićno-koštanog sustava i vezivnog tkiva bol u vratu, bol u leđima artralgija, mialgija
The standard approach to achieve elevated TSH levels has been to withdraw patients from thyroid hormone suppression therapy (THST), which usually causes patients to experience the signs and symptoms of hypothyroidism. 
Uobičajen pristup za postizanje povišene razine TSH-a je bio prekid supresijske terapije tireoidnim hormonom, što u bolesnika obično izaziva simptome i znakove hipotireoze.
Thyrogen is known to cause a transient but significant rise in serum thyroid hormone concentration when given to patients who have substantial thyroid tissue still in situ. 
Poznato je da Thyrogen uzrokuje prolazan ali značajan porast koncentracije hormona štitnjače u serumu kada se primijeni u bolesnika koji još uvijek imaju znatniju količinu tkiva štitnjače in situ.
All 28 patients (100%) treated after withdrawal of THST and all 32 patients (100%) treated after Thyrogen administration had either no visible uptake of radioiodine in the thyroid bed or, if visible, thyroid bed uptake <0.1% of the administered activity of radioiodine. 
U svih 28 bolesnika (100%) liječenih nakon prekida supresijske terapije tireoidnim hormonom te u svih 32 bolesnika (100%) liječenih nakon primjene lijeka Thyrogen ili nije bilo vidljivog nakupljanja radioaktivnog joda u ležištu štitnjače ili ono, ako je bilo vidljivo, nije premašilo < 0,1% primijenjene aktivnosti radioaktivnog joda.
How to store Thyrogen 
Kako primjenjivati Thyrogen
In clinical trials, for the detection of thyroid remnants or cancer in ablated patients using a thyroglobulin assay with a lower limit of detection of 0.5 ng/ml, Thyrogen-stimulated thyroglobulin levels of 3 ng/ml, 2 ng/ml and 1 ng/ml corresponded with thyroglobulin levels after withdrawal of thyroid hormone of 10 ng/ml, 5 ng/ml and 2 ng/ml, respectively. 
U kliničkim ispitivanjima otkrivanja ostatnog tkiva štitnjače ili karcinoma u bolesnika nakon provedene ablacije, primjenom tireoglobulinskog testa s donjom granicom detekcije od 0,5 ng/ml, razine tireoglobulina nakon stimulacije lijekom Thyrogen od 3 ng/ml, 2 ng/ml odnosno 1 ng/ml odgovarale su razinama tireoglobulina nakon prekida terapije tireoidnim hormonom od 10 ng/ml, 5 ng/ml odnosno 2 ng/ml.
Thyrogen-stimulated thyroglobulin levels were above 2 ng/ml in all 35 patients, whereas, thyroglobulin on THST was above 2 ng/ml in 79% of these patients. 
Nakon stimulacije lijekom Thyrogen vrijednosti tireoglobulina bile su iznad 2 ng/ml u svih 35 bolesnika, dok su uz primjenu supresijske terapije tireoidnim hormonom one bile iznad 2 ng/ml u 79% navedenih bolesnika.
The occurrence of antibodies which could interfere with endogenous TSH assays performed during regular follow-ups cannot be excluded. 
Ne može se isključiti stvaranje protutijela koja bi mogla interferirati s određivanjem vrijednosti endogenog TSH-a provedenog tijekom redovitog praćenja.
For diagnostic follow-up serum thyroglobulin (Tg) testing, the serum sample should be obtained 72 hours after the final injection of Thyrogen. 
Za dijagnostičko praćenje tireoglobulina (Tg) u serumu, uzorak seruma mora se uzeti 72 sata nakon zadnje injekcije lijeka Thyrogen.
Mannitol 
• manitol
The ESTIMABL1 study randomised 752 patients with low-risk thyroid cancer (tumour stages pT1 < 1 cm and N1 or Nx, pT1 >1-2 cm and any N stage, or pT2 N0, all patients M0) at 24 centres. 
ispitivanju ESTIMABL1 randomizirana su 752 bolesnika s tumorom štitnjače niskog rizika (stadiji tumora pT1 < 1 cm i N1 ili Nx, pT1 > 1-2 cm i bilo koji stadij
Some patients may feel dizzy or have headaches after administration of Thyrogen which may affect the ability to drive and use machines. 
Nakon primjene lijeka Thyrogen neki bolesnici mogu osjetiti omaglicu ili glavobolju, što može utjecati na sposobnost upravljanja vozilima i strojevima.
The success of thyroid remnant ablation also was assessed by the criterion of Thyrogen-stimulated serum Tg level < 2 ng/ml eight months after ablation, but only in patients who were negative for interfering anti-Tg antibodies. 
Uspješnost ablacije ostatnoga tkiva štitnjače ocjenjivala se i temeljem kriterija razine Tg u serumu nakon stimulacije lijekom Thyrogen od < 2 ng/ml osam mjeseci nakon ablacije, ali samo u bolesnika s negativnim nalazom interferirajućih anti-Tg protutijela.
There are no studies of alternative dose schedules of Thyrogen in patients with ESRD to guide dose reduction in this population. 
Ne postoje istraživanja o alternativnim režimima doziranja lijeka Thyrogen u bolesnika u terminalnoj fazi bubrežne bolesti na temelju kojih bi se definiralo smanjenje doze u toj populaciji.